<DOC>
	<DOC>NCT02514122</DOC>
	<brief_summary>A randomized double blind control trial to investigate the safety and efficacy of subcutaneous ketamine for control of post operative pain in low resource settings.</brief_summary>
	<brief_title>Subcutaneous Ketamine for Postoperative Pain Relief in Rwanda</brief_title>
	<detailed_description>A randomized double blind control trial. All patients undergoing upper abdominal, thoracic, gynecologic or orthopaedic surgeries at the Centre Hospitalier Universitaire de Kigali, Kigali, Rwanda will be invited to participate. Enrolled patients will receive subcutaneous ketamine (or placebo) administered immediately after surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections at a dose of 1mg/kg. The primary outcome will be a reduction in mean Pain Scores using parametric statistical analysis to discriminate significance. Pain will be measured using an 11-point numerical rating scale. Secondary outcomes will be the presence of significant side effects. This trial is a partnership between the University of Saskatchewan and the National University of Rwanda with ethics approval from each institutions ethics board.</detailed_description>
	<mesh_term>Pain, Postoperative</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<criteria>All patients undergoing upper abdominal, thoracic, gynecologic or orthopaedic surgeries during a one month period with expected post operative hospital admission Allergy to Ketamine History of narcotic abuse or dependence Those patients for which decreased cognitive function is a barrier to accurate data collection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>